The role of expanding intramedullary rods in osteogenesis imperfecta

1990 ◽  
Vol 25 (1) ◽  
pp. 176
Author(s):  
George C. Bennet
2016 ◽  
Vol 27 (7) ◽  
pp. 2355-2365 ◽  
Author(s):  
G. Brunetti ◽  
F. Papadia ◽  
A. Tummolo ◽  
R. Fischetto ◽  
F. Nicastro ◽  
...  

2008 ◽  
Vol 139 (7) ◽  
pp. 906-914 ◽  
Author(s):  
Cleonice Silveira Teixeira ◽  
Mara Cristina Santos Felippe ◽  
Wilson Tadeu Felippe ◽  
Yara Teresinha Corrêa Silva-Sousa ◽  
Manoel Damião Sousa-Neto

2021 ◽  
pp. 226-234
Author(s):  
L. Ya. Klimov ◽  
T. M. Vdovina ◽  
V. A. Pechenkina ◽  
T. V. Zhelezniakova ◽  
I. N. Zakharova ◽  
...  

The article presents the modern views of clinicians and geneticists on one of the most severe genetic disorders of skeletal and connective tissues - osteogenesis imperfecta. The review provided the literature data that showed the incidence rates, genetic heterogeneity of osteogenesis imperfecta, as well as the role of some proteins involved in the construction of bone tissue, as well as a clinical classification of the main types of the disorder. The authors described a clinical case: a girl with typical clinical and radiological manifestations of the rarest of all types of osteogenesis imperfecta - type II (perinatal-lethal, congenital osteogenesis imperfecta, Vrolik’s syndrome). The child’s diagnosis was verified by a parallel DNA sequence analysis which showed a heterozygous mutation in exon 29 (c.1966G> A) of COL1A1 gene not previously described in the literature. It caused the substitution of glycine for serine at position 656. The role of antenatal diagnostics and the importance of medical genetic counselling of the family before planning the next pregnancy due to the existing risk of re-birth of a sick child is outlined. Due to the fact that majority of the patients with the most prognostically unfavourable type II osteogenesis imperfecta, as a rule, die in utero, the described case of observation of the girl with typical clinical and X-ray signs of the disorder for almost 3 months of postpartum period is extremely rare and highly indicative. The detection of the heterozygous mutation in exon 29 (c.1966G > A) of COL1A1 gene by a parallel DNA sequence analysis which was not previously described in the literature gives an additional significance to the described observation.


2009 ◽  
Vol 19 (S2) ◽  
pp. 144-148 ◽  
Author(s):  
Carl Hans Fürstenberg ◽  
Thomas Grieser ◽  
Bernd Wiedenhöfer ◽  
Hans Jürgen Gerner ◽  
Cornelia Marianne Putz

2022 ◽  
Vol 5 (1) ◽  
pp. 01-09
Author(s):  
Parker J. Prusick ◽  
Steven D. Jones Jr. ◽  
Jesse Roberts ◽  
Nathan Donaldson

Bisphosphonate (BP) therapy for moderate to severe osteogenesis imperfecta (OI) has become a mainstay of treatment in the last three decades. Given the significant improvements in bone mineral density and theoretical reductions in fracture risk, many patients are treated with bisphosphonates for prolonged periods of time. There currently lacks consensus in the optimal duration of BP therapy for patients with OI, and patients are often treated on a case-by-case basis. Long-term BP therapy has been associated with atypical femur fractures in adult patients treated for osteoporosis. The American Society for Bone and Mineral Research concluded that the median duration of BP therapy in patients with atypical femur fractures was 7 years. The role of long-term BP therapy in OI patients with atypical femur fractures remains unclear. Here, a case report is presented of an adolescent patient with type V OI that sustained a subtrochanteric femur fracture with features of an atypical pattern following treatment with intravenous pamidronate for 10.5 years. At the time of injury, the contralateral femur was also found to have atypical features suggestive of an impending fracture. The completed fracture was treated with closed reduction and cephalomedullary nail fixation. The impending fracture was prophylactically stabilized using the same technique. Prior to the injury, limb-length radiographs obtained to evaluate lower extremity alignment demonstrated features of an impending fracture but went unnoticed. Further studies are needed to clarify the role of long-term BP therapy in patients with OI suffering from atypical femur fractures.


Sign in / Sign up

Export Citation Format

Share Document